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The main cause of prostate cancer-related mortality is the development of hormone-refractory disease. Circulating serum levels of IL-
6 are raised in hormone-refractory prostate cancer patients and evidence from cell line studies suggests that the IL-6R/JAK/STAT3
pathway may be involved in development of this disease. In the current study we investigate if expression levels of these family
members are implicated in the development of hormone-refractory prostate cancer. Immunohistochemistry using IL-6R, JAK1,
STAT3, pSTAT3
Tyr705 and pSTAT3
Ser727 antibodies was performed on 50 matched hormone-sensitive and hormone-refractory
tumours pairs. An increase in expression of cytoplasmic IL-6 receptor, with the development of hormone-refractory prostate cancer
was associated with reduced time to relapse (P¼0.0074) while an increase in expression of cytoplasmic pSTAT3
Tyr705 was
associated with reduced patient survival (P¼0.0003). In addition, those patients with high expression of cytoplasmic pSTAT3
Tyr705 in
their hormone-refractory tumours had significantly shorter time to death from biochemical relapse and overall survival in comparison
to those patients with low expression of cytoplasmic pSTAT3
Tyr705 (P¼0.002 and P¼0.0027, respectively). Activation of STAT3, via
phosphorylation is associated with reduced patient survival, suggesting that activation of the IL-6R/JAK/STAT3 pathway is involved
with development of hormone-refractory prostate cancer.
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Carcinoma of the prostate (CaP) is an increasing healthcare
problem. In the UK prostate cancer is the most common male
malignancy and is the second main cause of cancer-related deaths
among men. The majority of prostate cancer patients present with
locally advanced or metastatic disease, which may be treated using
androgen ablation therapy. Response rates to androgen ablation
therapy are initially high (70–80%), however most patients relapse
with resistance to androgen ablation within 18–24 months, termed
as developing hormone-refractory prostate cancer (Beemsterboer
et al, 1999). The lack of effective therapies directed against
hormone-refractory prostate cancer is related to the poor under-
standing of the molecular mechanisms that drive progression to
this refractory state (McEwan, 2004).
One possible mechanism underlying the development of
hormone-refractory prostate cancer is upregulation of the IL-6
receptor/JAK/STAT3 cascade. As prostate cancer progresses from
hormone sensitive to hormonerefractory, the circulating concen-
trations of IL-6 in the serum of patients increase (Fearon et al,
1991; Drachenberg et al, 1999; Heinrich et al, 2003). It is postulated
that this results in activation of the IL-6 receptor/JAK/STAT3
cascade (Hobisch et al, 1998), which has previously been reported
to increase androgen receptor (AR) activity (Culig, 2003). Indeed,
the increase in proliferation rate observed in prostate cancer cell
line models in response to IL-6 has been demonstrate to be via
activation of STAT3 (Dhir et al, 2002; Godoy-Tundidor et al, 2005;
Sanford and Dewille, 2005). In addition, in vitro studies have
demonstrated that IL-6-dependent activation of the JAK/STAT3
pathway is accompanied by transition from hormone-sensitive to
hormone-insensitive prostate cancer cell growth (Lee et al, 2003).
LNCaP cells, normally undergo apoptosis when androgens are
withdrawn, however treatment with IL-6 or transfection with
constitutively active STAT3 results in protection of the cells from
apoptosis and therefore resistance to androgen deprivation (Lee
et al, 2004). Inhibition of STAT3 activation results in the induction
of apoptosis in cells even in the presence of IL-6 (Barton et al,
2001, 2004). The hypothesis that STAT3 is involved in the
development of hormone-refractory prostate cancer is further
supported by the observation that levels of activated STAT3 are
significantly higher in AR-negative cells (DU145 and PC3) than in
AR-positive (LNCaP cells) (Mora et al, 2002). STAT3 activation
may therefore act to promote cell growth and survival in hormone-
refractory prostate cancer independent of the AR.
Conversely, STAT3 has been implicated in the development of
hormone-refractory disease via interaction with the AR (Culig,
2003, 2004). In LNCaP cells the activated dimer of STAT3 binds
ligand-free AR in the cytoplasm before entering the nucleus,
facilitating the translocation of the AR in to the nucleus in the
absence of androgens (Matsuda et al, 2001; Chen et al, 2002).
Functional cell line studies demonstrate that the AR/STAT-3
complex can promote androgen-regulated gene transcription even
in the absence of androgens (Chen et al, 2002; Trachtenberg and
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supported by data that demonstrate IL-6 can activate the AR in a
ligand-independent manner (Ueda et al, 2002; Corcoran and
Costello, 2003). Evidence in clinical tissue to support these in vitro
observations are sparse, although it is reported that IL-6 receptor
expression is eightfold higher in prostate cancer tissue compared
to normal tissue (Giri et al, 2001) and that phosphorylated STAT3
is observed in 82% of human prostate tumours and expression
levels correlate with Gleason score (Barton et al, 2004).
In summary, despite the large number of in vitro functional
reports implying a role of IL-6R/JAK/STAT3 pathway in prostate
cancer progression there appears to be little data confirming the
role of this pathway in the development of clinical hormone-
refractory prostate cancer. This study investigates both the
expression levels and activation of the IL-6R/JAK/STAT3 pathway
in matched hormone-sensitive and hormone-refractory tumours
from the same patient. This will enable us to assess if changes in
expression and activation of pathway members are associated with
development of hormone-refractory prostate cancer. Therefore,
we aim to identify whether inhibition of this pathway would lead
to improved patient outcome after progression to hormone-
refractory prostate cancer.
MATERIALS AND METHODS
Patients
Fifty patients were retrospectively selected for this study. Ethical
approval was obtained from the Multi-centre Research Ethics
Committee (MREC Scotland) and local research ethics committees.
Inclusion criteria for this study were that each patient was required
to have both hormone-sensitive and hormone-refractory tumours
available for analysis. Tumours were defined as hormone sensitive
if PSA fell by at least 50% during hormone treatment and
subsequently hormone refractory if two consecutive rises in serum
PSA of 410% was observed during hormone therapy.
Immunohistochemistry
All antibodies used in this study had specificity confirmed by
western blotting and on paraffin-embedded cell pellets known to
express the proteins of interest (LNCaP and MCF-7 cells). IHC was
performed on 5mm, archival formalin-fixed paraffin-embedded
prostate tumour sections. Two methods of antigen retrieval were
used, sections were microwaved under pressure (15psi) in TE
solution (5mM Tris base, pH 8.0 and 1mM sodium EDTA (JAK1,
3332; pSTAT3
Tyr705, 9131; and pSTAT3
Ser727, 9134, Cell Signaling
Technology) or incubated in 10mM citrate buffer (epitope retrieval
solution 10, DakoCytomation, Glostrup, Denmark) in a cali-
brated water bath at 961C for 20min (IL-6R, C20, SC-661, Santa
Cruz and STAT3, 9132, Cell Signaling Technology). Non-specific
background staining was blocked using 1.5% (v v
 1) normal horse
serum in tri-phosphate buffered saline and incubated for 20min at
room temperature. All antibodies were incubated overnight at 41C.
The concentrations used for each antibody were as follows: IL-6R
1:500, JAK1 1:100, STAT3 1:100, pSTAT3
Tyr705 1:50 and
pSTAT3
Ser727 1:50. Staining was developed using the LSAB plus
kit (DakoCytomation) and chromagen was detected using
3,3’diaminobenzidine (Vector Labs, UK). A positive and negative
control slide was included in each IHC run, negative controls were
incubated in an isotype-matched control antibody at a concentra-
tion of 1mgml
 1.
Scoring criteria
Tissue staining was scored blind by two independent observers
using a weighted histoscore method (Kirkegaard et al, 2006), also
known as the H score system (McCarty et al, 1986). The full tissue
section was examined and expression score calculated as follows
(1 % cells staining weakly positive)þ(2 % cells staining
moderately positive)þ(3 % cells staining strongly positive).
Maximum score was 300. An interclass correlation coefficient
(ICCC) for each protein was calculated by SPSS for Windows to
confirm consistency between observers and the mean of the two
observers’ scores were used for analysis. ICCC of greater than 0.7 is
considered as excellent (Kirkegaard et al, 2006).
Statistical analysis
Statistical analysis was performed using SPSS for Windows.
Descriptive analysis was used on variables such as age at diagnosis,
serum PSA (pre- and post-relapse), Gleason sum, time to
biochemical relapse, time to death from biochemical relapse and
overall survival. Median and inter-quartile (IQR) ranges were
calculated from these analyses. To determine if there was a change
in expression in progression from hormone-sensitive to hormone-
refractory disease a Wilcoxon signed-rank test was used to
compare the hormone-sensitive expression score to the hor-
mone-refractory expression score for each protein and each
location. Survival analysis was performed using Kaplan–Meier
curves and the log-rank test, low expression was defined as an
expression score less than or equal to the median and high
expression as expression score greater than the median. A change
in expression level in hormone-sensitive and hormone refractory-
matched tumours was defined as the mean difference between the
expression scores that each observer assigns for protein expression
plus two standard deviations. The number of histoscore units
defined as a change in expression for each individual protein is
shown in Table 1.
RESULTS
Patient characteristics
Fifty pairs of hormone-sensitive and hormone-refractory prostate
cancer tumours were analysed. The median age at diagnosis was 70
(IQR 64–73) years and the median PSA at diagnosis was 24.6 (IQR
6.4–79.8)ng ml
 1. The median time to biochemical relapse was
2.55 (IQR 1.55–5.24) years, the median time to death from
hormone relapse was 1.49 (IQR 0.98–2.14) years, and the median
overall survival was 5.82 (IQR 3.03–6.78) years. The median
Gleason sum was 8 (IQR 6–9) for hormone-sensitive tumours and
9 (IQR 8–9) for hormone-refractory tumours. The range of
Gleason sum for both tumour types was 2–10. All patients received
chemical or surgical castration and 39 also received anti-
androgens.
Table 1 The expression scores that represent a change in expression
levels in the transition from hormone-sensitive to hormone-refractory
disease
Mean difference+2 s.d. ICCC
IL-6R (membrane) 67.4 0.85
IL-6R (cytoplasmic) 33.7 0.83
JAK1 25.3 0.81
STAT3 32.5 0.86
pSTAT3
Tyr 705 (cytoplasmic) 31.5 0.70
pSTAT3
Tyr 705 (nuclear) 64.4 0.87
pSTAT3
Ser727 (cytoplasmic) 18.7 0.93
pSTAT3
Ser727 (nuclear) 54.9 0.87
These were calculated from the mean observer difference plus 2 standard deviations.
The inter- class correlation coefficients are also shown demonstrating consistent
scoring.
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The variation in observer scoring was calculated by ICCC. An
ICCC of 0.7 is classed as excellent and an ICCC of 1 indicates
identical scores. All scorer variations assessed in this study by
ICCC consistently achieved an ICCC of 0.7 or above, ICCC values
for each protein at each cellular location is given in Table 1.
Membrane and cytoplasmic expression was observed for IL-6
receptor, while only cytoplasmic expression was observed for
JAK1, and STAT3. Cytoplasmic and nuclear expression was seen
for both phosphorylated STAT3 proteins. An example of an
increase in expression for IL-6 receptor and pSTAT3
Tyr705 in the
transition from hormone-sensitive to hormone-refractory disease
is shown in Figure 1.
Protein expression levels in hormone-sensitive and
hormone-refractory tumours
To assess if protein expression levels were associated with clinical
endpoints (relapse and survival), Kaplan–Meier graphs were
plotted for tumours expressing low levels of specific proteins
compared to high levels. Those patients that expressed high levels
of cytoplasmic pSTAT3
Tyr705 in their hormone-refractory tumour
had significantly shorter time to death from biochemical relapse
and than those patients with low cytoplasmic pSTAT3
Tyr705
expression (P¼0.002, hazard ratio 4.25 (95% CI 1.59–11.34))
(Figure 2A). This also translated into significantly shorter overall
survival (P¼0.0027, hazard ratio 2.87 (95% CI 1.39–5.92))
(Figure 2B). The median overall survival in those patients whose
tumours expressed high levels was 3.77 (IQR 1.11–6.43) years
compared to 7.55 (IQR 6.69–8.41) years for those whose tumours
expressed low levels. A trend with overall survival was also noted
for nuclear pSTAT3
Tyr705 in hormone-refractory prostate cancer;
however due to the lines crossing after 8 years this was not
significant (P¼0.250) (Figure 2C). The median overall survival for
those patients whose tumours had low expression was 7.49 (IQR
6.52–8.57) years compared to 5.82 (IQR 3.49–8.15) years for
those patients whose tumours expressed high levels of nuclear
pSTAT3
Tyr705. Expression levels of all other proteins in hormone-
sensitive or hormone-refractory tumours were not associated
with time to relapse, time to death from relapse, or overall
survival. When pSTAT3
Tyr705 and pSTAT3
Ser727 expression levels
were divided by Gleason (o7, 7 or 47) no change in expression
was observed in the cytoplasm or the nucleus. In addition the ratio
of pSTAT3
Tyr705 and pSTAT3
Ser727 does not correlate with Gleason.
Changes in protein expression with the development of
hormone-refractory prostate cancer
An increase in cytoplasmic IL-6 receptor expression from
hormone sensitive to hormone refractory was associated with
reduced time to biochemical relapse (P¼0.0074) (Figure 3). The
median time to relapse for patients whose tumours had a decrease
or no change in expression with the development of hormone-
refractory prostate cancer was 2.97 (IQR 1.89–4.07) year compared
to 1.18 (IQR 0.45–1.92) years for those patients whose tumours
exhibited a rise in expression.
An increase in expression of cytoplasmic pSTAT3
Tyr705 with
progression to hormone-refractory prostate cancer was also
associated with a reduction in overall survival (P¼0.0003, hazard
ratio 4.52 (95% CI 1.85–11.52)) (Figure 4A). The median overall
survival for those patients whose tumours exhibited a decrease or
no change in expression was 7.54 (IQR 6.52–8.57) years compared
to 5.51 (IQR 2.77–8.26) years for those patients whose tumours
IL-6 receptor
Hormone sensitive Hormone refractory
×400 ×400
pSTAT3 705
Hormone sensitive Hormone refractory
×400 ×400
Figure 1 Images of matched hormone-sensitive and hormone-refractory prostate tumours whose expression increased in the transition from hormone-
sensitive to hormone-refractory disease (upper panel: IL-6 receptor and lower panel: pSTAT3
Tyr705). Positive staining is brown in colour and is indicated by
arrows according to their location, M, membrane; C, cytoplasm; and N, nucleus. Counterstaining is blue and is represented in the stroma (S).
JAK/STAT expression in prostate cancer
L Tam et al
380
British Journal of Cancer (2007) 97(3), 378–383 & 2007 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sexhibited a rise in expression. Changes in the expression levels of
all the other proteins investigated in the transition from hormone-
sensitive to hormone-refractory tumours were not significantly
associated with time to relapse, time to death from relapse, or
overall survival.
DISCUSSION
Approximately 50% of patients with advanced prostate cancer have
elevated levels of serum IL-6 in comparison with men with normal
prostates, benign prostatic hyperplasia, prostatitis and localised
disease (Twillie et al, 1995; Drachenberg et al, 1999). In addition
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Figure 2 (A) Kaplan–Meier plot comparing time to death from biochemical relapse for those patients with hormone-refractory tumours with high
cytoplasmic pSTAT3
Tyr705 expression (solid line) (27 patients) compared to those patients with hormone-refractory tumours with low cytoplasmic
pSTAT3
Tyr705 expression (broken line) (23 patients) (P¼0.002, hazard ratio 4.2 (95% CI 1.59–11.34)). (B) Kaplan–Meier plot comparing overall survival
for those patients with hormone-refractory tumours with high-cytoplasmic pSTAT3
Tyr705 expression (solid line) (19 patients) compared to those patients
with hormone-refractory tumours with low cytoplasmic pSTAT3
Tyr705 expression (broken line) (31 patients) (P¼0.0027, hazard ratio 2.87 (95% CI 1.39–
5.92)). (C) Kaplan–Meier plot for high-pSTAT3
Tyr705 protein expression in the nucleus vs low nuclear pSTAT3
Tyr705 protein expression in hormone-
refractory prostate tumours. Those patients with high pSTAT3
Tyr705 (solid line) (22 patients) expression had shorter overall survival compared to those with
low pSTAT3
Tyr705 (broken line) (28 patients); however this was not a significant change (P¼0.25).
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Figure 3 Kaplan–Meier plot for an increase in IL-6R protein expression
vs no change or a decrease in IL-6R protein expression in the transition
from hormone-sensitive to hormone-refractory disease. Those patients
with an increase in IL-6R expression (solid line) (six patients) had
significantly shorter time to biochemical relapse compared to those with no
change or a decrease in IL-6R expression (broken line) (45 patients)
(P¼0.0076, hazard ratio 3.45 (95% CI 1.31–9.07)).
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Figure 4 Kaplan–Meier plot for an increase in pSTAT3
Tyr705 protein
expression in the cytoplasm vs no change or a decrease in pSTAT3
Tyr705
protein expression in the transition from hormone-sensitive to hormone-
refractory disease. Those patients with an increase in pSTAT3
Tyr705 (solid
line) (nine patients) expression had significantly shorter overall survival
compared to those with no change or a decrease in pSTAT3
Tyr705
expression (broken line) (50 patients) (P¼0.0003, hazard ratio 4.52 (95%
CI 1.85–11.52)).
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to hormone-insensitive disease in animal models via interaction
with AR cofactors (Wallner et al, 2006). One possible mode by
which IL-6 may influence progression of prostate cancer to the
hormone-refractory state is by activating the IL-6 receptor/JAK1/
STAT3 pathway, resulting in differentiation and inhibition of
apoptosis (Spiotto and Chung, 2000a; Smith et al, 2001). Over-
expression of IL-6 receptor in androgen-sensitive human LNCaP
cells results in the conversion to androgen-independent growth
both in vitro and in vivo (Lee et al, 2003) and depletion of IL-6
results in decreased proliferation of hormone-insensitive cells but
not hormone-sensitive cells (Lou et al, 2000).
The IL-6 receptor is predominantly located in the cell membrane
(Lou et al, 2000), however the IL-6/IL-6 receptor complex may be
taken into the cell by endocytosis as part of the protein-recycling
process (Nesbitt and Fuller, 1992). This is the cell’s method of
downregulating receptors once the ligand has produced the
appropriate signal (Nesbitt and Fuller, 1992). Therefore as the
IL-6 receptor, unlike the other signalling proteins in the pathway
does not have a phosphorylated form, the localisation of the IL-6
receptor to the cytoplasm may be used as a surrogate marker for
activation. This study demonstrates that there is an association
with an increase in cytoplasmic IL-6 receptor expression with
development of hormone-refractory prostate cancer and time to
biochemical relapse. However these results should be treated with
caution as only 12% (six patients) of the patients in our cohort
exhibited this increase. We would therefore aim to increase our
cohort size to confirm these results.
JAK1 and STAT3 are proteins that become activated in
sequence, upon the binding of IL-6 to the IL-6 receptor (Schindler
and Darnell, 1995). STAT3 is phosphorylated at two different sites,
tyrosine 705 position and serine 727. The tyrosine kinase, JAK1
phosphorylates STAT3 at tyrosine 705, while the kinase(s) that
mediate serine phosphorylation remain to be determined, evidence
suggests that mitogen-activated protein kinase may be responsible
(Briscoe et al, 1996a, b). Immunohistochemical staining in our
cohort of patients has demonstrated that both phosphorylated
forms of STAT3, pSTAT3
Tyr705 and pSTAT3
Ser727 are found in the
cytoplasmic and nuclear compartments of the cell. STAT3
dimerisation occurs in the cytoplasm before it enters the nucleus
(Corcoran and Costello, 2003), the presence of activated STAT3 in
the cytoplasm, therefore, provides a ‘snapshot’ of activated STAT3
before it enters the nucleus. Although it has been previously
reported that it is serine phosphorylation at 727 that modulates the
DNA binding and/or transcriptional activity of STAT3 dimers
(Dhir et al, 2002) our data shows no evidence of pSTAT3
Ser727
being associated with development of hormone-refractory prostate
cancer. However, it has been reported that phosphorylation of
STAT3 at serine 727 via ERK1 and/or 2 negatively regulates STAT3
activity (Kim et al, 2002; Tian et al, 2004), this supports our data
that pSTAT3
Ser727 is not associated with the development of hormone-
refractory prostate cancer or prostate cancer patient survival.
There does however appear to be a significant role for
pSTAT3
Tyr705 in the progression to hormone-refractory prostate
cancer. High expression of cytoplasmic pSTAT3
Tyr705 in hormone-
refractory prostate cancer tissue is associated with quicker time to
death from hormone relapse and shorter overall survival. In
addition, an increase in pSTAT3
Tyr705 with the development of
hormone-refractory prostate cancer is associated with shorter
overall survival. These results fit with the hypothesis that
activation of the IL-6 receptor/JAK1/STAT3 pathway is involved
in the development of hormone-refractory prostate cancer.
However, nuclear expression of pSTAT3
Tyr705 expression was not
associated with clinical parameters in this study. This may be due
to the fact that although phosphorylation of tyrosine 705 increases
STAT3 activity it is not sufficient to induce its relocation from the
cytoplasm to the nucleus. Dimerisation of STAT3 is required for its
translocation to the nucleus and this is regulated by reversible
acetylation of a single lysine (Lys) residue (position 685) (Yuan
et al, 2005). More research is therefore required to understand the
exact mechanisms for activation and translocation of STAT3 to the
nucleus and also the consequence of STAT3 phosphorylation in
clinical prostate cancer tissue. Cell line studies demonstrate that
STAT3 activation results in an increase in proliferation and
induces neuroendocrine differentiation, although out with the
scope of the current study these parameters warrant further
investigation in clinical tissue to establish the route by which
STAT3 influences prostate cancer patient survival (Spiotto and
Chung, 2000b).
In summary, these data support the hypothesis that the IL-6
receptor/JAK1/STAT3 pathway is activated in the progression of
hormone-refractory prostate cancer. Cytoplasmic expression of IL-
6 receptor and pSTAT3
Tyr705 are associated with reduced time to
biochemical relapse and reduced time to death from hormone
relapse respectively, therefore, supporting the strategy for targeting
this pathway in hormone-refractory prostate cancer treatments. A
recent report demonstrates that this pathway can be targeted and
successfully inhibited in other disease using a humanised mono-
clonal antibody that targets the IL-6 receptor (in a similar to which
herceptin targets HER2 (Jia et al, 2004; Nakahara and Nishimoto,
2006; Nishimoto and Kishimoto, 2006) and this approach has
proved successful in prostate cancer animal models (Wallner et al,
2006). Use of this drug (tocilixumab) in phase II clinical trials for
rheumatoid arthritis has proved the clinical benefit of IL-6 blockade
and we suggest that such a strategy should be applied to hormone-
refractory (Nishimoto and Kishimoto, 2006).
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